Phase III ,Randomized,Placebo-Conrolled,Muticenter,Double-Blind Study Comparing JS001 Combined With Chemotherapy Versus Placebo Combined With Chemotherapy for Recurrent or Metastatic Nasophapyngeal Cancer
Phase of Trial: Phase III
Latest Information Update: 13 Mar 2019
Price : $35 *
At a glance
- Drugs Toripalimab (Primary) ; Cisplatin; Gemcitabine
- Indications Nasopharyngeal cancer
- Focus Registrational; Therapeutic Use
- Sponsors Shanghai Junshi Biosciences
- 07 Mar 2019 Planned End Date changed from 21 Aug 2020 to 21 Aug 2021.
- 27 Nov 2018 Status changed from not yet recruiting to recruiting.
- 13 Jul 2018 New trial record